RARE

Ultragenyx Pharmaceutical Inc.
$23.94 +2.92%

Recent alerts on RARE

All signals →
Insider trade Sale by Horn Howard (Chief Financial Officer)
12h ago
News Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical - Benzinga
14d ago
News Leerink Partners upgrades Ionis stock on key asset commercialization - Investing.com
14d ago
Insider trade Sale by SULIMAN SHEHNAAZ
14d ago
News Ultragenyx (RARE) Posts New Data From Bone Disease Study
14d ago
News Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
14d ago
News Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
14d ago
News Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
14d ago
SEC filing RARE Stockholders Approve Third Amended 2023 Incentive Plan, Elect Class I Directors, Ratify Ernst & Young LLP as Auditor
14d ago
Insider trade Sale by Eric Crombez (EVP and Chief Medical Officer)
26d ago
SEC filing RARE Reports $136M Q1 Rev, $730-760M 2026 Guidance, Crysvita $93M, Dojolvi $18M, GTX-102 Phase 3 Data 2H26
27d ago
Insider trade Sale by Howard Horn (Chief Financial Officer)
28d ago
News Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data
69d ago
News Mereo downgraded at JP Morgan on setrusumab regulatory uncertainty
70d ago
News Ultragenyx posts late-stage trial win for gene therapy in urea cycle disorder
81d ago
SEC filing RARE Announces Positive Phase 3 DTX301 Data: 18% Ammonia Reduction, 71% Much Improved, $150M Spend
82d ago
Scanner Unusual buy pressure (5.2x avg, 75% up-volume, +3.9% / +0.85 intraday, above VWAP)
84d ago
Insider trade Sale by John Richard Pinion (EVP, Chief Quality Operations Officer)
90d ago
Insider trade Sale by Erik Harris (EVP & Chief Commercial Officer)
90d ago
Insider trade Sale by Emil D Kakkis (President & CEO)
90d ago
Insider trade Sale by Howard Horn (Chief Financial Officer)
90d ago
Insider trade Sale by Eric Crombez (EVP and Chief Medical Officer)
90d ago
Insider trade Sale by Karah Herdman Parschauer (EVP and Chief Legal Officer)
90d ago
Insider trade Sale by Theodore Alan Huizenga (SVP, Chief Accounting Officer)
90d ago
SEC filing RARE FDA Accepts BLA for DTX401 Gene Therapy, Grants Priority Review for GSDIa Treatment
98d ago

Get push alerts for RARE

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS